Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. [electronic resource]
Producer: 20191021Description: 2033-2039 p. digitalISSN:- 1592-8721
- Adult
- Anthracyclines -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Arsenic Trioxide -- administration & dosage
- Belgium
- Disease-Free Survival
- Female
- France
- Humans
- Leukemia, Promyelocytic, Acute -- diagnosis
- Male
- Middle Aged
- Switzerland
- Treatment Outcome
- Tretinoin -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.